ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 7 for:    8435513 [PUBMED-IDS]

Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03157284
Recruitment Status : Active, not recruiting
First Posted : May 17, 2017
Last Update Posted : May 17, 2017
Sponsor:
Information provided by (Responsible Party):
Heinz Italia SpA

Brief Summary:
This Study Evaluate the efficacy of the subministration of fermented rice flour (7 g/day) on the clinical course of patients with moderate or severe Atopic Dermatitis, in terms of a reduction in the SCORAD score, during the study period and four weeks after the suspension of the treatment.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Dietary Supplement: Rice Flour Dietary Supplement: Placebo Not Applicable

Detailed Description:

It is scientifically recognised that some probiotic effects can be obtained from inactivated bacteria or isolated bacterial components (e.g. bacterial DNA) or factors produced during fermentation (short-chain fatty acids, bacterial proteins, etc.) (7). This category also includes the ingredient which forms the focus of this trial: fermented rice flour, prepared from rice flour fermented by a probiotic (Lactobacillus paracasei CBA L74) which was heat-inactivated at the end of the fermentation process. The finished product, therefore, does not contain live bacteria.

The bacterium used - owned by the sponsor and filed with the BCCM/LMG bacteria collection - belongs to the species Lactobacillus paracasei, and is included in the Qualified Presumption of Safety (QPS) list of microorganisms compiled by the European Food Safety Authority's Panel on Biological Hazards (8). The bacterium has been tested for its sensitivity to antibiotics on the basis of the relevant criteria drawn up by the EFSA (9) and its genomic sequence is known. Pre-clinical studies have shown anti-inflammatory effects of food matrices fermented with Lactobacillus paracasei CBA L74 (stimulating the production of IL-10 and the reduction of IL-12), and in response to stimulation with Salmonella typhimurium (10). Recently, the clinical effects of the consumption of rice flour fermented with Lactobacillus paracasei CBA L74 for 12 weeks were tested in a pilot study conducted on children with moderate/severe AD (defined using the SCORAD index) (11). In this study, all the children reported an improvement in the severity of the AD and reduced topical steroid application frequency.

Considering the rationale for the use of live or inactivated probiotics or isolated bacterial components for the treatment of AD as well as the clinical studies in the paediatric population that have shown encouraging results (11), this randomised, double-blind, placebo-controlled trial aims to evaluate the efficacy of rice flour fermented with Lactobacillus paracasei CBA L74 in subjects with AD; in particular, this trial will evaluate the clinical response in terms of the severity of the AD during and at the end of a 12-week treatment period and four weeks after the suspension of the treatment.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis : Randomized, Double-Blind, Placebo-Controlled Trial
Actual Study Start Date : January 23, 2017
Estimated Primary Completion Date : July 1, 2017
Estimated Study Completion Date : March 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo Group will receive 7gr Maltodextrin
Dietary Supplement: Placebo
For 12 weeks a group of children will receive a 7gr of a placebo (maltodextrin), according to a randomised, double-blind design.

Experimental: Intervention Rice Flour
The Intervention Group will receive 7gr of the experimental ingredient fermented Rice Flour
Dietary Supplement: Rice Flour
For 12 weeks, a group of children will receive 7gr fermented rice flour according to a randomised, double-blind design.




Primary Outcome Measures :
  1. Reduction in the SCORAD score [ Time Frame: 16 weeks ]

    Standardised questionnaire for calculating the SCORAD score:

    Evaluate the efficacy of the administration of fermented rice flour (7 g/day) on the clinical course of patients with moderate or severe Atopic Dermatitis, in terms of a reduction in the SCORAD score, during the study period and four weeks after the suspension of the treatment



Secondary Outcome Measures :
  1. Inflammatory response :Peripheral immunophenotype analysis and Cytokine profile [ Time Frame: 12 weeks ]
    Evaluate the inflammatory response at baseline (T0) and at the end of treatment (T12) in terms of inflammation markers (cytokine profile) and peripheral immunophenotype compared to the placebo group.Peripheral cytokine assay (IFNγ, IL-4, IL-5, IL-10, IL-12, IL-13, IL-18, IL-31) at baseline and after specific stimulation (anti-CD3/CD28) or non-specific stimulation (PHA) on all enrolled children.

  2. Allergic sensitisation:Total and specific IgE (sIgE) assay [ Time Frame: 12 weeks ]
    Evaluate allergic sensitisation by total and specific IgE (sIgE) assay at baseline (T0) and at the end of treatment (T12) compared to the placebo group

  3. Steroids prescription [ Time Frame: 16 weeks ]
    Evaluate the prescription of topical steroid therapy in the group of children treated with fermented rice flour compared to the placebo group.

  4. Faecal microbiota analysis [ Time Frame: 12 weeks ]
    Evaluate the change in intestinal microbial flora between T0 and T12



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Months to 36 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children between 6 and 36 months old, gradually enrolled from among patients attending the Paediatric Dermatology and Allergy Clinic
  • Diagnosis of moderate or severe Atopic Dermatitis, evaluated using the SCORAD index

Exclusion Criteria:

  • Rhinitis and/or acute asthma
  • Chronic diseases (autoimmune diseases, Cronic Obstructive Pulmunary Disease, heart disease, Congenital Nephrotic diseases, diabetes, acquired or congenital immunodeficiency)
  • Treatment with prebiotics and/or probiotics in the month prior to enrolment
  • Ongoing antibiotic therapy
  • Treatment with systemic immunomodulators in the month prior to enrolment
  • Treatment with topical immunomodulators (tacrolimus or pimecrolimus) in the three months prior to enrolment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03157284


Locations
Italy
Ospedale dei Bambini Vittore Buzzi-Clinica Pediatrica
Milano, Italy
Sponsors and Collaborators
Heinz Italia SpA
Investigators
Principal Investigator: Gian Vincenzo Zuccotti, Prof Clinica Pediatrica Ospedale dei Bambini Vittore Buzzi

Publications:

Responsible Party: Heinz Italia SpA
ClinicalTrials.gov Identifier: NCT03157284     History of Changes
Other Study ID Numbers: FERCT16
First Posted: May 17, 2017    Key Record Dates
Last Update Posted: May 17, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Heinz Italia SpA:
Lactobacillus, Probiotics

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases